Investigational New Drugs

, Volume 36, Issue 2, pp 288–298 | Cite as

A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

  • Muhammad Alamgeer
  • D. Neil Watkins
  • Ilia Banakh
  • Beena Kumar
  • Daniel J. Gough
  • Ben Markman
  • Vinod Ganju
PHASE II STUDIES
  • 129 Downloads

Summary

Preclinical studies in small cell lung cancer (SCLC) have shown that hyaluronic acid (HA) can be effectively used to deliver chemotherapy and selectively decrease CD44 expressing (stem cell-like) tumour cells. The current study aimed to replicate these findings and obtain data on safety and activity of HA-irinotecan (HA-IR). Eligible patients with extensive stage SCLC were consented. A safety cohort (n = 5) was treated with HA-IR and Carboplatin (C). Subsequently, the patients were randomised 1:1 to receive experimental (HA-IR + C) or standard (IR + C) treatment, to a maximum of 6 cycles. The second line patients were added to the study and treated with open label HA-IR + C. Tumour response was measured after every 2 cycles. Baseline tumour specimens were stained for CD44s and CD44v6 expression. Circulating tumour cells (CTCs) were enumerated before each treatment cycle. Out of 39 patients screened, 34 were evaluable for the study. The median age was 66 (range 39–83). The overall response rates were 69% and 75% for experimental and standard arms respectively. Median progression free survival was 42 and 28 weeks, respectively (p = 0.892). The treatments were well tolerated. The incidence of grade III/IV diarrhea was more common in the standard arm, while anaemia was more common in the experimental arm. IHC analysis suggested that the patients with CD44s positive tumours may gain survival benefit from HA-IR. HA-IR is well tolerated and active in ES-SCLC. The effect of HA-IR on CD44s + cancer stem-like cells provide an early hint towards a potential novel target.

Keywords

Small cell lung cancer CD44 Hyaluronic acid Cancer stem cells 

Notes

Acknowledgements

The authors thank Peter Midolo and Zdenka Prodanivc for their technical support.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Alamgeer M, Ganju V, Kumar B et al. (2014) Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer breast cancer research : BCR 16:R44, doi: https://doi.org/10.1186/bcr3648
  2. 2.
    Alamgeer M, Ganju V, Szczepny A et al (2013) The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 68:1095–1104.  https://doi.org/10.1136/thoraxjnl-2012-203021 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical cancer research : an official journal of the American Association for Cancer Research 10:6897–6904.  https://doi.org/10.1158/1078-0432.CCR-04-0378 CrossRefGoogle Scholar
  4. 4.
    Ando M, Kobayashi K, Yoshimura A et al (2004) Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44:121–127.  https://doi.org/10.1016/j.lungcan.2003.10.003 CrossRefPubMedGoogle Scholar
  5. 5.
    Ardizzoni A, Manegold C, Debruyne C et al (2003) European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 9:143–150Google Scholar
  6. 6.
    Auzenne E, Ghosh SC, Khodadadian M et al (2007) Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 9:479–486CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Brown MB, Jones SA (2005) Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. Journal of the European Academy of Dermatology and Venereology : JEADV 19:308–318.  https://doi.org/10.1111/j.1468-3083.2004.01180.x CrossRefPubMedGoogle Scholar
  8. 8.
    Burris HA 3rd (1998) Topotecan: incorporating it into the treatment of solid tumors. Oncologist 3:1–3PubMedGoogle Scholar
  9. 9.
    Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 7:1748–1756CrossRefGoogle Scholar
  10. 10.
    Chen G, Huynh M, Fehrenbacher L et al (2009) Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27:1401–1404.  https://doi.org/10.1200/JCO.2008.20.2127 CrossRefGoogle Scholar
  11. 11.
    Chua YJ, Steer C, Yip D (2004) Recent advances in management of small-cell lung cancer. Cancer Treat Rev 30:521–543.  https://doi.org/10.1016/j.ctrv.2004.06.003 CrossRefPubMedGoogle Scholar
  12. 12.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMedGoogle Scholar
  13. 13.
    Dalla Pozza E, Lerda C, Costanzo C et al (2013) Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochim Biophys Acta 1828:1396–1404.  https://doi.org/10.1016/j.bbamem.2013.01.020 CrossRefPubMedGoogle Scholar
  14. 14.
    Fukuoka M, Furuse K, Saijo N et al (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855–861CrossRefPubMedGoogle Scholar
  15. 15.
    Ganesh S, Iyer AK, Morrissey DV, Amiji MM (2013) Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34:3489–3502.  https://doi.org/10.1016/j.biomaterials.2013.01.077 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gibbs P, Brown TJ, Ng R et al (2009) A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. Chemotherapy 55:49–59.  https://doi.org/10.1159/000180339 CrossRefPubMedGoogle Scholar
  17. 17.
    Gibbs P, Clingan PR, Ganju V et al (2011) Hyaluronan-irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother Pharmacol 67:153–163.  https://doi.org/10.1007/s00280-010-1303-3 CrossRefPubMedGoogle Scholar
  18. 18.
    Han D, Wang G, Sun L, Ren X, Shang W, Xu L, Li S (2017) Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: a meta-analysis. Eur J Cancer Care (Engl) 26.  https://doi.org/10.1111/ecc.12723
  19. 19.
    Hanna N, Bunn PA, Jr., Langer C et al. (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24:2038–2043 doi: https://doi.org/10.1200/JCO.2005.04.8595
  20. 20.
    Hermes A, Bergman B, Bremnes R et al (2008) Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 26:4261–4267.  https://doi.org/10.1200/JCO.2007.15.7545 CrossRefPubMedGoogle Scholar
  21. 21.
    Hiraga T, Ito S, Nakamura H (2013) Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res 73:4112–4122.  https://doi.org/10.1158/0008-5472.CAN-12-3801 CrossRefPubMedGoogle Scholar
  22. 22.
    Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H (1998) Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 58:1108–1110PubMedGoogle Scholar
  23. 23.
    Kurup A, Hanna NH (2004) Treatment of small cell lung cancer. Crit Rev Oncol Hematol 52:117–126.  https://doi.org/10.1016/j.critrevonc.2004.08.005 CrossRefPubMedGoogle Scholar
  24. 24.
    Lara PN Jr, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535.  https://doi.org/10.1200/JCO.2008.20.1061 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Luo Z, RR W, Lv L, Li P, Zhang LY, Hao QL, Li W (2014) Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol 7:3632–3646PubMedPubMedCentralGoogle Scholar
  26. 26.
    Masuda N, Fukuoka M, Furuse K (1992a) CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. Oncology 49(Suppl 1):19–24CrossRefPubMedGoogle Scholar
  27. 27.
    Masuda N, Fukuoka M, Kusunoki Y et al (1992b) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10:1225–1229CrossRefGoogle Scholar
  28. 28.
    Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S (2011) Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278:1429–1443.  https://doi.org/10.1111/j.1742-4658.2011.08071.x CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mizera-Nyczak E, Dyszkiewicz W, Heider KH, Zeromski J (2001) Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 22:45–53CrossRefGoogle Scholar
  30. 30.
    Naito T, Tanaka F, Ono A et al (2012) Prognostic impact of circulating tumor cells in patients with small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 7:512–519.  https://doi.org/10.1097/JTO.0b013e31823f125d CrossRefGoogle Scholar
  31. 31.
    Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91.  https://doi.org/10.1056/NEJMoa003034 CrossRefPubMedGoogle Scholar
  32. 32.
    Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46:1271–1277.  https://doi.org/10.1016/j.ejca.2010.02.024 CrossRefPubMedGoogle Scholar
  33. 33.
    Pan D, Hou M, Li H, Yu P, Liu J (2006) Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: a randomized clinical trial. Zhongguo Fei Ai Za Zhi 9:443–446.  https://doi.org/10.3779/j.issn.1009-3419.2006.05.11 PubMedGoogle Scholar
  34. 34.
    Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45.  https://doi.org/10.1038/nrm1004 CrossRefPubMedGoogle Scholar
  35. 35.
    Pure E, Cuff CA (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7:213–221CrossRefPubMedGoogle Scholar
  36. 36.
    Ramalingam S, Belani CP, Day R, Zamboni BA, Jacobs SA, Jett JR (2004) Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 15:247–251CrossRefGoogle Scholar
  37. 37.
    Reeder JA, Gotley DC, Walsh MD, Fawcett J, Antalis TM (1998) Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res 58:3719–3726PubMedGoogle Scholar
  38. 38.
    Rosenthal MA, Gibbs P, Brown TJ et al (2005) Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. Chemotherapy 51:132–141.  https://doi.org/10.1159/000085621 CrossRefPubMedGoogle Scholar
  39. 39.
    Roth BJ, Johnson DH, Einhorn LH et al (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the southeastern cancer study group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10:282–291CrossRefGoogle Scholar
  40. 40.
    Roudi R, Madjd Z, Korourian A, Mehrazma M, Molanae S, Sabet MN, Shariftabrizi A (2014) Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer biomarkers : section A of Disease markers 14:457–467.  https://doi.org/10.3233/CBM-140424 CrossRefPubMedGoogle Scholar
  41. 41.
    Sandler AB (2003) Chemotherapy for small cell lung cancer. Semin Oncol 30:9–25.  https://doi.org/10.1053/sonc.2003.50012 CrossRefPubMedGoogle Scholar
  42. 42.
    Schmittel A, Sebastian M, Fischer von Weikersthal L et al (2011) A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22:1798–1804.  https://doi.org/10.1093/annonc/mdq652 CrossRefPubMedGoogle Scholar
  43. 43.
    Schuette W (2001) Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer 33(Suppl 1):S99–107CrossRefPubMedGoogle Scholar
  44. 44.
    Seiter S, Arch R, Reber S et al (1993) Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177:443–455CrossRefPubMedGoogle Scholar
  45. 45.
    Shi Y, Hu Y, Hu X, Li X, Lin L, Han X (2015) Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: a multicenter randomized controlled clinical trial. Thorac Cancer 6:785–791.  https://doi.org/10.1111/1759-7714.12303 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Simon GR, Wagner H, American College of Chest P (2003) Small Cell Lung Cancer Chest 123:259S–271SPubMedGoogle Scholar
  47. 47.
    Tran TA, Kallakury BV, Sheehan CE, Ross JS (1997) Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 28:809–814CrossRefPubMedGoogle Scholar
  48. 48.
    van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378:1741–1755.  https://doi.org/10.1016/S0140-6736(11)60165-7 CrossRefPubMedGoogle Scholar
  49. 49.
    Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768.  https://doi.org/10.1038/nrc2499 CrossRefPubMedGoogle Scholar
  50. 50.
    Wimmel A, Schilli M, Kaiser U et al (1997) Preferential histiotypic expression of CD44-isoforms in human lung cancer. Lung Cancer 16:151–172CrossRefPubMedGoogle Scholar
  51. 51.
    Zatloukal P, Cardenal F, Szczesna A et al (2010) A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 21:1810–1816.  https://doi.org/10.1093/annonc/mdq036 CrossRefPubMedGoogle Scholar
  52. 52.
    Zeilstra J, Joosten SP, Vermeulen L et al (2013) CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. PLoS One 8:e72849.  https://doi.org/10.1371/journal.pone.0072849 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Zhang MQ, Lin X, Li Y, Lu S (2015) Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: a Systemic Analysis Asian Pacific journal of cancer prevention : APJCP 16:1993–1995PubMedGoogle Scholar
  54. 54.
    Zhao S, He JL, Qiu ZX, Chen NY, Luo Z, Chen BJ, Li WM (2014) Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP 15:6761–6766CrossRefPubMedGoogle Scholar
  55. 55.
    Zoller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11:254–267.  https://doi.org/10.1038/nrc3023 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Medical OncologyMonash Medical CentreClaytonAustralia
  2. 2.Centre for Cancer ResearchHudson Institute of Medical ResearchClaytonAustralia
  3. 3.Monash UniversityClaytonAustralia
  4. 4.The Kinghorn Cancer CentreGarvan Institute of Medical ResearchDarlinghurstAustralia
  5. 5.Department of PathologyMonash Medical CentreClaytonAustralia
  6. 6.Peninsula and Southeast OncologyFrankstonAustralia

Personalised recommendations